HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Tolterodine

HCID 443879
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
124937-51-5
Standard SMILES
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1
InChIKey
OOGJQPCLVADCPB-HXUWFJFHSA-N
Molecular formula
C22H31NO
Average molar mass
325.5 g/mol
Monoisotopic mass
325.24056461

Overview

Tolterodine is a tertiary amine. It has a role as a muscarinic antagonist, a muscle relaxant and an antispasmodic drug. It is functionally related to a p-cresol.

Names & identifiers

Preferred name
Tolterodine
IUPAC
2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol
English name
Tolterodine
Molecular formula
C22H31NO
Molecular weight
325.49

Names & synonyms

tolterodine124937-51-5(+)-TolterodineTolterodinumKabi 2234TolterodinaKabi-22342-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenolWHE7A56U7K(+)-(R)-2-(alpha-(2-(Diisopropylamino)ethyl)benzyl)-p-cresolCHEBI:96222-[(1R)-3-[bis(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol
Show more names
DETROLTOLTERODINE L-TARTRATEPNU-20058EDETRUSITOLPNU 200583Tolterodine-d6TolterodineBaseTolterodine-d14
Detrusitol xlEfflosomyl xlMariosea xlPreblacon xlSantizor xl2-((1R)-3-(bis(propan-2-yl)amino)-1-phenylpropyl)-4-methylphenol2-((1R)-3-(di(propan-2-yl)amino)-1-phenylpropyl)-4-methylphenol2-[(1R)-3-(di(propan-2-yl)amino)-1-phenylpropyl]-4-methylphenol

Database identifiers

CAS
124937-51-5
PubChem CID
443879
DTXSID

Properties

Computed structural properties

XLogP
5.6
Topological polar surface area
23.5 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
2
Rotatable bonds
7
Heavy atoms
24
Formal charge
0
Complexity
340

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15
LogP5.6
Solubility5.34e-03 g/L
Human DrugsBreast Feeding; Lactation; Milk, Human; Muscarinic Antagonists; Parasympatholytics
Endocrine DisruptorsPotential endocrine disrupting compound
Physical DescriptionSolid
Dissociation Constants9.8
Collision Cross Section182.1 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

Physicochemical properties

alpha
25 · D25 +72° (c = 1.0 in CH2Cl2)
Boiling point

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P203, P264, P270, P280, P301+P316, P318, P321, P330, P405, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Hazard information

Hazard Classes and CategoriesAcute Tox. 3 (100%)

Toxicology

Hepatotoxicity · 1 item

In multiple randomized controlled trials of tolterodine in patients with overactive bladder syndrome, serum aminotransferase and alkaline phosphatase elevations were not common, arising in less than 1% of treated subjects and in a similar proportion of placebo recipients. In these clinical trials there were no reports of clinically apparent liver injury or jaundice. Since the approval of tolterodine in 1998 and its widescale use (with more than 1 million prescriptions filled yearly in the United States), there has been only one published case report of liver injury with symptoms and jaundice attributed to its use (Case 1). Thus, acute symptomatic liver injury due to tolterodine must be very rare, if it occurs at all.

Adverse EffectsAdverse effects of tolterodine are significantly lower than that of other antimuscarinic drugs indicated for the same use.
Toxicity Summary · 1 item

To prevent toxicity, patients with hepatic impairment should be given a lower dose since the drug's elimination is lower than that of healthy patients. Additionally, tolterodine demonstrated higher concentrations in patients with renal impairment. Therefore, recommendations include a decrease in drug dosage in both patients with hepatic or renal impairment.

Chemistry & industry

Pharmacology

ATC Code · 3 items

G04BD07

G - Genito urinary system and sex hormones

QG - Genito urinary system and sex hormones

Protein BindingApproximately 96.3%.
Pharmacodynamics · 1 item

Tolterodine is a competitive muscarinic receptor antagonist. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors. After oral administration, tolterodine is metabolized in the liver, resulting in the formation of the 5-hydroxymethyl derivative, a major pharmacologically active metabolite. The 5-hydroxymethyl metabolite, which exhibits an antimuscarinic activity similar to that of tolterodine, contributes significantly to the therapeutic effect. Both tolterodine and the 5-hydroxymethyl metabolite exhibit a high specificity for muscarinic receptors, since both show negligible activity or affinity for other neurotransmitter receptors and other potential cellular targets, such as calcium channels. Tolterodine has a pronounced effect on bladder function. The main effects of tolterodine are an increase in residual urine, reflecting an incomplete emptying of the bladder, and a decrease in detrusor pressure, consistent with an antimuscarinic action on the lower urinary tract.

Mechanism of Action · 1 item

Both tolterodine and its active metabolite, 5-hydroxymethyltolterodine, act as competitive antagonists at muscarinic receptors. This antagonism results in inhibition of bladder contraction, decrease in detrusor pressure, and an incomplete emptying of the bladder.

Biological Half-Life1.9-3.7 hours
Metabolism/MetabolitesTolterodine has known human metabolites that include 5-Hydroxymethyl tolterodine and N-Dealkylated tolterodine.
FDA Pharmacological Classification · 6 items

WHE7A56U7K

TOLTERODINE

Established Pharmacologic Class [EPC] - Cholinergic Muscarinic Antagonist

Related reactions

26 records
New reaction record
HRID 29228 reaction equation
HRID 29228As product
HRID 217309 reaction equation
HRID 217309As product
HRID 237179 reaction equation
HRID 237179As product
HRID 384425 reaction equation
HRID 384425As reactant
HRID 384426 reaction equation
HRID 384426As reactant
HRID 384427 reaction equation
HRID 384427As reactant
HRID 384428 reaction equation
HRID 384428As reactant
HRID 384429 reaction equation
HRID 384429As reactant
PreviousPage 1 of 4

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
DTXSID3023687
ChEMBL
CHEMBL1382
ChEBI
CHEBI:9622
UNII
WHE7A56U7K
EC Number
805-304-4
Nikkaji
J561.859B
442.2 · 442.2±45.0 °C(Predicted)
Density
1.003 · 1.003±0.06 g/cm3(Predicted)
storage temp.
-20 °C · -20°C Freezer
solubility
20 mg/mL · DMSO: ≥20mg/mL
pka
9.8 · pKa 9.8 (Uncertain)
form
powder
color
white to off-white
CAS DataBase Reference
124937 · 124937-51-5(CAS DataBase Reference)
FDA UNII
7 A56U7K · WHE7A56U7K
ATC code
4 BD07 · G04BD07
Comptox DTXSID
3023687 · DTXSID3023687
Symbol(GHS)
6 · GHS06,GHS08
Signal word
Danger
Hazard statements
301 · H301-H361
Precautionary statements
281 · P281-P301+P310
Hazard Codes
Xn,N
Risk Statements
63 · 63-51/53
Safety Statements
22 · 22-36/37-57
WGK Germany
3 · 3
Drug Induced Liver Injury · 5 items

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

tolterodine

DILI Negative

Oral

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

wgk
3
risk_code
63-51/53
Signal word
Danger
Symbol(GHS)
GHS06,GHS08
hazard_code
Xn,N
safety_code
22-36/37-57
Hazard statements
H301-H361
Precautionary statements
P281-P301+P310

Mechanisms of Action [MoA] - Cholinergic Muscarinic Antagonists

Tolterodine is a Cholinergic Muscarinic Antagonist. The mechanism of action of tolterodine is as a Cholinergic Muscarinic Antagonist.

TOLTERODINE

MeSH Pharmacological Classification · 2 items

Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.

Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS.

Absorption, Distribution and Excretion · 2 items

Following administration of a 5-mg oral dose of 14C-tolterodine solution to healthy volunteers, 77% of radioactivity was recovered in urine and 17% was recovered in feces in 7 days.

113 ± 26.7 L

Cellular LocationsMembrane

Uses & manufacturing

UsesUse (kg; approx.) in Germany (2009): >50
Applications · 2 items

UsesA muscarinic receptor antagonist. Used in the treatment of urinary incontinence.

General DescriptionTolterodine (Detrol), 2-[3-[bis(1-methylethyl)amino]-1-phenyl-propyl]-4-methyl-phenol, is an antimuscarinicagent that acts on M2 and M3 muscarinic subtypereceptors. By competitively blocking of the muscarinicreceptors results in a reduction of the smooth muscle tone,allowing for greater volume of urine to be stored in the bladder.This results in less urinary incontinence, urgency, andfrequency.

Upstream & downstream products

Upstream raw materials

p-CresolCentchromanLauric acidIsopropyl alcoholSulfuric acidHydrochloric acidSodium hydroxideDiisobutylaluminium hydridePalladium hydroxideCinnamic acidDiisopropylaminetrans-Cinnamic acidL(+)-Tartaric acidPotassium carbonateSodium carbonateCitric acid

Additional notes

DefinitionChEBI: Tolterodine is a tertiary amine. It has a role as a muscarinic antagonist, a muscle relaxant and an antispasmodic drug. It is functionally related to a p-cresol.